Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Left Main PCI Technique Could Change DAPT Duration

Up to 20% of patients undergoing left main PCI require a 2-stent technique, and this number should most likely grow after the DKCRUSH-V outcomes. However, this study contradicts the DKCRUSH-V and brings us back to “the simpler the better”, since patients undergoing 1 stent left main PCI presented less revascularization and less target vessel failure than patients undergoing 2 stent PCI. Even more, it suggests extending DAPT when using a 2-stent technique.

La ATC es una alternativa válida en el TCIThe aim of this study was to assess the impact of DAPT duration according to the chosen technique to treat left main bifurcations.

 

Researchers analyzed 5 multicenter registries looking into a combination of target vessel failure and thrombotic events, in addition to differences in the individual components. They carried out a subgroup analyzis according to DAPT duration.


Read also: DKCRUSH-V: What Is Simple Is Not Always Best for the Left Main Coronary Artery.


Of the 13172 registry patients undergoing PCI with new generation stents, 700 received left main bifurcation PCI (567 with 1 stent and 133 with 2 stents).

 

Target vessel failure and revascularization rates were higher in the 2-stent group (most lesions were more anatomically complex).

 

Thrombotic event risk was comparable between both strategies, though the subgroup analyzis showed the 2-stent group had a significantly higher risk when receiving DAPT for 1 year, while the risk was similar when DAPT went on for longer.  


Read also: EXCEL-QOL Substudy: Similar Quality of Life both with CABG and Left Main PCI.


This study shows that complex PCI might help redefine DAPT duration.

 

Original title: Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention.

Reference: Tae-Min Rhee et al. J Am Coll Cardiol Intv 2018;11:2453–63.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...